They presented scientific results, which are by their nature complex
that does not require them to present it in a complex, or frankly awful, way. Did you even look at their slide deck? Its an utter eye sore, moreso than usual pharma slide decks.
How is that NKTR’s fault?
Well, it was their presentation… Having a higher share price is beneficial for them when they need to raise additional funds, negotiate a buy out, etc. I do not think many publicly traded biotechs are going, “oh good, our share price fell 40% today!”
If the data was so great, then they should have done a better job explaining it.
¯_(?)_/¯